Loading clinical trials...
Loading clinical trials...
It is a single-arm, open-label clinical study to assess the safety and efficacy of the Anti-CD19 Universal CAR-T Cells injection for patients with CD19+ refractory/relapsed B cell acute lymphoblastic ...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Collaborators
NCT06189391 · Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
NCT05054257 · Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma Refractory, and more
NCT04690595 · Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
NCT06824701 · Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
NCT05008055 · Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Kunming, Yunnan
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions